3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Neoplasm Metastasis
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
11
Nivolumab
4
Erlotinib Hydrochloride
3
Docetaxel
3
Cetuximab
3
Capecitabine
3
tislelizumab
2
spartalizumab
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Immunoglobulin G
2
Gemcitabine
2
Filgrastim
2
Cyclophosphamide
2
tremelimumab
1
sargramostim
1
ribociclib
1
poly ICLC
1
pexidartinib
1
mirabegron
1
futibatinib
1
etoposide phosphate
1
entinostat
1
durvalumab
1
ciforadenant
1
cemiplimab
1
capivasertib
1
bempegaldesleukin
1
avelumab
1
X-Rays
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
futibatinib
×
Sarcoma
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled